Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here

Pricing and Ordering Information

 

Women's Health: U.S. Markets for Reproductive Management Products
Report #A471
- September 2013
132 Pages – 31 Exhibits – 7 Company Profiles


The U.S. market for reproductive management products is large and robust, estimated at more than $3.7 billion in 2013. This market, which includes a broad range of contraceptive drugs, contraceptive devices/implants, and fertility drugs, is expected to expand at a healthy compound annual growth rate of more than 7%, increasing by more than $1.5 billion over a span of 5 years.

Despite a sluggish economy, intense competition, pricing pressures, litigation, and the significant impact of generic contraceptives, growth in this market is expected to accelerate at a better than average pace throughout the forecast period, as the contraceptives segment, in particular, benefits from highly positive insurance reimbursement (as a result of the 2010 Affordable Care Act) and increasing consumer affordability. The contraceptives market is also expected to flourish due to the introduction of several safer, more tolerable, lower-dosage, yet highly effective contraceptive drugs, and strong advertising/marketing efforts by major pharmaceutical firms. Additionally, the market is benefiting from increased consumer preference and usage of novel contraceptive devices and implants, which provide a convenient, long-term alternative for preventing pregnancy, especially in women who cannot tolerate, or fail to adhere to required dosing schedules of oral drug therapies.

The U.S. market for reproductive management products will also benefit from continued strong demand for easier-to-use, highly effective fertility drugs, as well as the introduction of new technologies, which are expected to enhance assisted reproductive technology and further improve pregnancy rates and decrease potential side effects.

Overall, the U.S. market for reproductive management products will continue to benefit from the stability and growth of the aging female population in the U.S., which continues to postpone or refrain from childbearing and demand access to highly effective contraceptives and fertility drugs.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include oral, transdermal, injectable and emergency contraceptives; contraceptive devices, including intrauterine devices (IUDs), vaginal rings, and subdermal contraceptive implants; and leading fertility drug therapies and devices, among other products.

Ordering Information

Title

Report# Publication
Date
List Price

Women's Health: U.S. Markets for Reproductive Management Products

A471

September 2013

$3,750

Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.          Contraceptive Drugs and Devices

ii.          Fertility Treatment

iii.         Combined Market Forecast

iv.         Methodology

 

Exhibit ES-1:    Reproductive Management Products Market, Combined Market Forecast, 2012-2017

Exhibit ES-2:    Reproductive Management Products, Market Forecast, by Product Segment, 2012-2017

Exhibit ES-3:    2012, Reproductive Management Products Market, Share of Sales, by Product Segment

Exhibit ES-4:    2017, Reproductive Management Products Market, Share of Sales, by Product Segment

 

1. CONTRACEPTIVE DRUGS AND DEVICES

1.1 Contraceptive Drugs

1.1.1 Actavis

1.1.2 Bayer

1.1.3 Janssen Pharmaceuticals/Johnson & Johnson

1.1.4 Merck & Company

1.1.5 Pfizer

1.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries

1.1.7 Market Forecast

1.1.8 Competitive Analysis

1.2 Contraceptive Devices

1.2.1 Actavis

1.2.2 Bayer

1.2.3 The Female Health Company

1.2.4 FemCap

1.2.5 Mayer Laboratories

1.2.6 Merck & Company

1.2.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries

1.2.8 Market Forecast

1.2.9 Competitive Analysis

1.3 Nonsurgical Sterilization

1.3.1 Bayer

1.3.2 Hologic

 

Exhibit 1-1:      2013, Selected Contraceptive Drugs

Exhibit 1-2:      2013, Selected Contraceptive Drugs Under Development

Exhibit 1-3:      The Average Reduction in Menstrual Bleeding Using Natazia Over a 90-day Assessment Phase in 2 Studies

Exhibit 1-4:      Contraceptive Drugs, Market Forecast, 2012-2017

Exhibit 1-5:      2012, Contraceptive Drugs Market, Share by Supplier

Exhibit 1-6:      2013, Selected Leading Contraceptive Devices

Exhibit 1-7:      2013, Selected Contraceptive Devices Under Development

Exhibit 1-8:      The Mirena Intrauterine Device

Exhibit 1-9:      The FemCap Cervical Cap

Exhibit 1-10:    The NuvaRing Vaginal Contraceptive Ring

Exhibit 1-11:    Efficacy of the NuvaRing Compared to Other Contraceptive Methods

Exhibit 1-12:    The Implanon Subdermal Contraceptive Implant

Exhibit 1-13:    Efficacy of Implanon Compared to Other Contraceptive Methods

Exhibit 1-14:    The ParaGard Intrauterine Device

Exhibit 1-15:    Contraceptive Devices, Market Forecast, 2012-2017

Exhibit 1-16:    2012, Contraceptive Devices Market, Share by Supplier

Exhibit 1-17:    The Essure Three-Step Sterilization Procedure

 

2. FERTILITY DRUGS AND DEVICES

2.1 Selected Fertility Drug Treatments

2.1.1 Actavis

2.1.2 EMD Serono/Merck KGaA

2.1.3 Ferring Pharmaceuticals

2.1.4 Merck & Company

2.1.5 OvaScience

2.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries

2.1.7 Market Forecast

2.1.8 Competitive Analysis

2.2 Embryo Transfer Catheters

2.2.1 CooperSurgical/The Cooper Companies

2.2.2 Irvine Scientific/JX Group

2.3 Assisted Natural Conception

3.3.1 Cambridge Temperature Concepts

 

Exhibit 2-1:      2013, Selected Fertility Drug Therapies

Exhibit 2-2:      2013, Selected Immunoassays and Fertility Treatments Under Development

Exhibit 2-3:      Efficacy of Crinone in Maintaining Full-Term Pregnancies Following In Vitro Fertilization Embryo Transfer

Exhibit 2-4:      Efficacy of Crinone in Maintaining Full-Term Pregnancies versus No Supplemental Progesterone for Luteal Phase Support

Exhibit 2-5:      The Gonal-f RFF Pen

Exhibit 2-6:      Fertility Drugs, Market Forecast, 2012-2017

Exhibit 2-7:      2012, Fertility Drugs Market, Share by Supplier

Exhibit 2-8:      The R.G. Edwards Embryo Transfer Catheters

Exhibit 2-9:      The Classic Ultrasoft Embryo Transfer Catheters and Stylets

Exhibit 2-10:    The DuoFertility Assisted Natural Conception System

 

3. COMPANY PROFILES

3.1       Actavis, Inc.

3.2       Bayer AG

3.3       Ferring Pharmaceuticals A/S

3.4       Johnson & Johnson

3.5       Merck & Company, Inc.

3.6       Merck KGaA

3.7       Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD

 

APPENDIX:  COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact custcare@informa.com. You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.800.332.2181) or fax 1.908.748.1222.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home